Cargando…

Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)

The vast majority of SARS-CoV-2 vaccines which are licensed or under development focus on the spike (S) protein and its receptor binding domain (RBD). However, the S protein shows considerable sequence variations among variants of concern. The aim of this study was to develop and characterize a SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabdano, Sevastyan O., Ruzanova, Ellina A., Pletyukhina, Iuliia V., Saveliev, Nikita S., Kryshen, Kirill L., Katelnikova, Anastasiia E., Beltyukov, Petr P., Fakhretdinova, Liliya N., Safi, Ariana S., Rudakov, German O., Arakelov, Sergei A., Andreev, Igor V., Kofiadi, Ilya A., Khaitov, Musa R., Valenta, Rudolf, Kryuchko, Daria S., Berzin, Igor A., Belozerova, Natalia S., Evtushenko, Anatoly E., Truhin, Viktor P., Skvortsova, Veronika I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141225/
https://www.ncbi.nlm.nih.gov/pubmed/37112786
http://dx.doi.org/10.3390/vaccines11040874
_version_ 1785033342091001856
author Rabdano, Sevastyan O.
Ruzanova, Ellina A.
Pletyukhina, Iuliia V.
Saveliev, Nikita S.
Kryshen, Kirill L.
Katelnikova, Anastasiia E.
Beltyukov, Petr P.
Fakhretdinova, Liliya N.
Safi, Ariana S.
Rudakov, German O.
Arakelov, Sergei A.
Andreev, Igor V.
Kofiadi, Ilya A.
Khaitov, Musa R.
Valenta, Rudolf
Kryuchko, Daria S.
Berzin, Igor A.
Belozerova, Natalia S.
Evtushenko, Anatoly E.
Truhin, Viktor P.
Skvortsova, Veronika I.
author_facet Rabdano, Sevastyan O.
Ruzanova, Ellina A.
Pletyukhina, Iuliia V.
Saveliev, Nikita S.
Kryshen, Kirill L.
Katelnikova, Anastasiia E.
Beltyukov, Petr P.
Fakhretdinova, Liliya N.
Safi, Ariana S.
Rudakov, German O.
Arakelov, Sergei A.
Andreev, Igor V.
Kofiadi, Ilya A.
Khaitov, Musa R.
Valenta, Rudolf
Kryuchko, Daria S.
Berzin, Igor A.
Belozerova, Natalia S.
Evtushenko, Anatoly E.
Truhin, Viktor P.
Skvortsova, Veronika I.
author_sort Rabdano, Sevastyan O.
collection PubMed
description The vast majority of SARS-CoV-2 vaccines which are licensed or under development focus on the spike (S) protein and its receptor binding domain (RBD). However, the S protein shows considerable sequence variations among variants of concern. The aim of this study was to develop and characterize a SARS-CoV-2 vaccine targeting the highly conserved nucleocapsid (N) protein. Recombinant N protein was expressed in Escherichia coli, purified to homogeneity by chromatography and characterized by SDS-PAGE, immunoblotting, mass spectrometry, dynamic light scattering and differential scanning calorimetry. The vaccine, formulated as a squalane-based emulsion, was used to immunize Balb/c mice and NOD SCID gamma (NSG) mice engrafted with human PBMCs, rabbits and marmoset monkeys. Safety and immunogenicity of the vaccine was assessed via ELISA, cytokine titer assays and CFSE dilution assays. The protective effect of the vaccine was studied in SARS-CoV-2-infected Syrian hamsters. Immunization induced sustainable N-specific IgG responses and an N-specific mixed Th1/Th2 cytokine response. In marmoset monkeys, an N-specific CD4(+)/CD8(+) T cell response was observed. Vaccinated Syrian hamsters showed reduced lung histopathology, lower virus proliferation, lower lung weight relative to the body, and faster body weight recovery. Convacell(®) thus is shown to be effective and may augment the existing armamentarium of vaccines against COVID-19.
format Online
Article
Text
id pubmed-10141225
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101412252023-04-29 Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®) Rabdano, Sevastyan O. Ruzanova, Ellina A. Pletyukhina, Iuliia V. Saveliev, Nikita S. Kryshen, Kirill L. Katelnikova, Anastasiia E. Beltyukov, Petr P. Fakhretdinova, Liliya N. Safi, Ariana S. Rudakov, German O. Arakelov, Sergei A. Andreev, Igor V. Kofiadi, Ilya A. Khaitov, Musa R. Valenta, Rudolf Kryuchko, Daria S. Berzin, Igor A. Belozerova, Natalia S. Evtushenko, Anatoly E. Truhin, Viktor P. Skvortsova, Veronika I. Vaccines (Basel) Article The vast majority of SARS-CoV-2 vaccines which are licensed or under development focus on the spike (S) protein and its receptor binding domain (RBD). However, the S protein shows considerable sequence variations among variants of concern. The aim of this study was to develop and characterize a SARS-CoV-2 vaccine targeting the highly conserved nucleocapsid (N) protein. Recombinant N protein was expressed in Escherichia coli, purified to homogeneity by chromatography and characterized by SDS-PAGE, immunoblotting, mass spectrometry, dynamic light scattering and differential scanning calorimetry. The vaccine, formulated as a squalane-based emulsion, was used to immunize Balb/c mice and NOD SCID gamma (NSG) mice engrafted with human PBMCs, rabbits and marmoset monkeys. Safety and immunogenicity of the vaccine was assessed via ELISA, cytokine titer assays and CFSE dilution assays. The protective effect of the vaccine was studied in SARS-CoV-2-infected Syrian hamsters. Immunization induced sustainable N-specific IgG responses and an N-specific mixed Th1/Th2 cytokine response. In marmoset monkeys, an N-specific CD4(+)/CD8(+) T cell response was observed. Vaccinated Syrian hamsters showed reduced lung histopathology, lower virus proliferation, lower lung weight relative to the body, and faster body weight recovery. Convacell(®) thus is shown to be effective and may augment the existing armamentarium of vaccines against COVID-19. MDPI 2023-04-20 /pmc/articles/PMC10141225/ /pubmed/37112786 http://dx.doi.org/10.3390/vaccines11040874 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rabdano, Sevastyan O.
Ruzanova, Ellina A.
Pletyukhina, Iuliia V.
Saveliev, Nikita S.
Kryshen, Kirill L.
Katelnikova, Anastasiia E.
Beltyukov, Petr P.
Fakhretdinova, Liliya N.
Safi, Ariana S.
Rudakov, German O.
Arakelov, Sergei A.
Andreev, Igor V.
Kofiadi, Ilya A.
Khaitov, Musa R.
Valenta, Rudolf
Kryuchko, Daria S.
Berzin, Igor A.
Belozerova, Natalia S.
Evtushenko, Anatoly E.
Truhin, Viktor P.
Skvortsova, Veronika I.
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title_full Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title_fullStr Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title_full_unstemmed Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title_short Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)
title_sort immunogenicity and in vivo protective effects of recombinant nucleocapsid-based sars-cov-2 vaccine convacell(®)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141225/
https://www.ncbi.nlm.nih.gov/pubmed/37112786
http://dx.doi.org/10.3390/vaccines11040874
work_keys_str_mv AT rabdanosevastyano immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT ruzanovaellinaa immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT pletyukhinaiuliiav immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT savelievnikitas immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT kryshenkirilll immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT katelnikovaanastasiiae immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT beltyukovpetrp immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT fakhretdinovaliliyan immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT safiarianas immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT rudakovgermano immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT arakelovsergeia immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT andreevigorv immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT kofiadiilyaa immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT khaitovmusar immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT valentarudolf immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT kryuchkodarias immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT berzinigora immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT belozerovanatalias immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT evtushenkoanatolye immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT truhinviktorp immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell
AT skvortsovaveronikai immunogenicityandinvivoprotectiveeffectsofrecombinantnucleocapsidbasedsarscov2vaccineconvacell